Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 19/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17476241 | 0.90 | OGA (0.66) | OGAHTTSMN1; SMN2 | |
| SCHEMBL20023194 | 0.89 | OGA (0.64) | OGAHTTSMN1; SMN2 | |
| SCHEMBL16112712 | 0.89 | OGA (0.64) | OGAHTTSMN1; SMN2 | |
| SCHEMBL16113762 | 0.88 | OGA (0.66) | OGAHTTSMN1; SMN2 | |
| SCHEMBL16112788 | 0.87 | OGA (0.65) | OGAHTTSMN1; SMN2 | |
| SCHEMBL16112962 | 0.87 | OGA (0.62) | OGAHTTSMN1; SMN2 | |
| SCHEMBL16113559 | 0.86 | OGA (0.80) | OGAHTTSMN1; SMN2 | |
| SCHEMBL16113758 | 0.84 | OGA (0.58) | OGAHTTSMN1; SMN2 | |
| SCHEMBL16113629 | 0.83 | OGA (0.66) | OGAHTTSMN1; SMN2 | |
| SCHEMBL17476245 | 0.82 | OGA (0.65) | OGAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301299-B2 | Glycosidase inhibitors | MERCK PATENT GMBH (DE) | 2019-05-28 | — | — | US | disclosed |
| US-10301299-B2 | Glycosidase inhibitors | MERCK PATENT GMBH (DE) | 2019-05-28 | — | — | US | disclosed |
| US-20180093977-A1 | Glycosidase Inhibitors | MERCK PATENT GMBH (DE) | 2018-04-05 | — | — | US | disclosed |
| US-20180093977-A1 | Glycosidase Inhibitors | MERCK PATENT GMBH (DE) | 2018-04-05 | — | — | US | disclosed |
| US-20180093977-A1 | Glycosidase Inhibitors | MERCK PATENT GMBH (DE) | 2018-04-05 | — | — | US | disclosed |
| CN-105143222-B | Glycosidase inhibitor | 默克专利有限公司 | 2018-02-02 | — | — | CN | disclosed |
| US-9879001-B2 | Glycosidase inhibitors | MERCK PATENT GMBH (DE) | 2018-01-30 | — | — | US | disclosed |
| US-9879001-B2 | Glycosidase inhibitors | MERCK PATENT GMBH (DE) | 2018-01-30 | — | — | US | disclosed |
| US-9879001-B2 | Glycosidase inhibitors | MERCK PATENT GMBH (DE) | 2018-01-30 | — | — | US | disclosed |
| US-20160031871-A1 | Glycosidase Inhibitors | YU HENRY (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031871-A1 | Glycosidase Inhibitors | YU HENRY (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031871-A1 | Glycosidase Inhibitors | YU HENRY (US) | 2016-02-04 | — | — | US | disclosed |
| CN-105143222-A | Glycosidase inhibitors | MERCK PATENT GMBH | 2015-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031871-A1 | Glycosidase Inhibitors | GAA, BACE1, GBA3 | OGA 127/4885HTT 1009/4885SMN1; SMN2 1348/4885 |
| US-10301299-B2 | Glycosidase inhibitors | GAA, BACE1, GBA3 | OGA 127/4885HTT 1009/4885SMN1; SMN2 1348/4885 |
| US-20180093977-A1 | Glycosidase Inhibitors | GAA, BACE1, GBA3 | OGA 127/4885HTT 1009/4885SMN1; SMN2 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.